Purpose: To evaluate the repeatability of an extensive number of relevant indices with the Pentacam HR in keratoconus of varying severity and normal eyes.
Design: Reliability analysis.
Methods: This study was performed at Antwerp University Hospital, Belgium, and enrolled 20 healthy volunteers (20 eyes) and 69 patients (69 eyes) with keratoconus. Three consecutive measurements were performed by the same operator with Pentacam HR in keratoconus and normal eyes. Exclusion criteria included past ocular surgery, recent rigid contact lens wear, and corneal scarring. The keratoconus group was subdivided according to the Belin/Ambrosio total deviation value: subclinical, mild, and moderate. The within-subject standard deviation and repeatability limit were computed for repeatability assessment. The tolerance index (TI) was calculated to compare across parameters with different measurement scales. For the sample size included, TI > 0.36 signified statistical significance at the 0.05 level.
Results: Repeatability in subclinical keratoconus did not differ significantly from controls (P > .05), except for wavefront aberrations. In mild keratoconus, 11 of 18 (61.1%) anterior corneal, 7 of 14 (50%) posterior corneal, 2 of 5 (40%) pachymetry, 7 of 11 (63.6%) combined, and 1 of 6 (16.7%) densitometry parameters showed significantly worse repeatability compared to controls (TI > 0.36). Repeatability of most parameters worsened in moderate disease. In particular, maximal keratometry and anterior astigmatism showed significantly worse repeatability in moderate keratoconus.
Conclusions: Measurement variability of Pentacam HR is of clinical relevance when assessing for progression of keratoconus. We provide reference repeatability values and scale independent analysis of relevant corneal parameters in keratoconus of varying degrees.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajo.2020.06.013 | DOI Listing |
Viruses
December 2024
Faculty of Science and Technology, University of Canberra, Canberra, ACT 2617, Australia.
The global burden of respiratory syncytial virus (RSV) and severe associated disease is prodigious. RSV-specific vaccines have been launched recently but there is no antiviral medicine commercially available. RSV polymerase (L) protein is one of the promising antiviral targets, along with fusion and nucleocapsid proteins.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Center for Advanced Technologies, Tashkent 100174, Uzbekistan.
The development of effective and safe vaccines and their timely delivery to the public play a crucial role in preventing and managing infectious diseases. Many vaccines have been produced and distributed globally to prevent COVID-19 infection. However, establishing effective vaccine development platforms and evaluating their safety and immunogenicity remains critical to increasing health security, especially in developing countries.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania.
Given that COVID-19 vaccination is a relatively recent development, particularly when compared to immunisation against other diseases, it is crucial to assess its efficacy in vaccinated populations. This literature review analysed studies that monitored antibody titres against SARS-CoV-2 in healthcare workers who received COVID-19 vaccines. Using the PICO (Population, Intervention, Comparators, Outcomes) model recommended in the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines we included 43 publications which analyse antibody dynamics following primary vaccination, the effects of booster doses, and the influence of factors such as COVID-19C infection, age, and sex on antibody kinetics.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Department of Microbiology, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
Background/objectives: The emergence of the Omicron variant has complicated COVID-19 control and prompted vaccine updates. Recent studies have shown that a fourth dose significantly protects against infection and severe disease, though long-term immunity data remain limited. This study aimed to assess Anti-S-RBD antibodies and interferon-γ levels in healthcare workers 12 months after receiving bivalent Original/Omicron BA.
View Article and Find Full Text PDFVaccines (Basel)
December 2024
Laboratorio de Vacunas Veterinarias, Departamento de Ciencias Biológicas Animales, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santa Rosa 11735, La Pintana, Santiago 8820808, Chile.
Immunization against Gonadotropin-Releasing Hormone (GnRH) has been successfully explored and developed for the parenteral inoculation of animals, aimed at controlling fertility, reducing male aggressiveness, and preventing boar taint. Although effective, these vaccines may cause adverse reactions at the injection site, including immunosuppression and inflammation, as well as the involvement of laborious and time-consuming procedures. Oral vaccines represent an advancement in antigen delivery technology in the vaccine industry.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!